Meningiomas occurring during long-term survival after treatment for childhood cancer by Sugden, E. et al.
Clinical Review
Meningiomas occurring during long-term survival
after treatment for childhood cancer
Elaine Sugden1, Aliki Taylor2, Pieter Pretorius3, Colin Kennedy4 and Ranj Bhangoo5
136, North Hinksey Village, Oxford, OX2 0 NA, UK
2Birmingham University, Birmingham B15 2TT, UK
3Oxford University Hospitals, Oxford OX3 9DU, UK
4University Hospital Southampton, Southampton SO16 6YD, UK
5Kings College Hospital Foundation Trust, London SE5 9RS, UK
Corresponding author: Elaine Sugden. Email: elainesugden@doctors.org.uk
Summary
Childhood cancer is rare but improvements in treatment
over the past five decades have resulted in a cohort of
more than 30,000 long-term survivors of childhood
cancer in the UK with more added annually. These long-
term survivors are at risk of late effects of cancer treatment
which replace original tumour recurrence as the leading
cause of premature death. Second neoplasms are a particu-
lar risk and in the central nervous system meningiomas
occur increasingly with increased radiation dose to central
nervous system tissue and length of time after exposure,
resulting in a 500-fold increase above that expected in the
normal population by 40 years of follow up. This multidis-
ciplinary author group and others met to discuss the issue.
Our pooled information, and consensus that screening
should only follow symptoms, was published online by
the Royal College of Radiologists in 2013. We outline
here the current knowledge and management of these neo-
plasms secondary to childhood cancer treatment.
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Introduction
Although cancer in children (0–14 years) accounts for
only 0.5% of UK cancer incidence with an average of
1500 cases per year, there are now of the order of
33,000 adults in the UK who during childhood were
treated for cancer and are classed as long-term sur-
vivors.1 The majority of childhood cancers cannot be
cured by local treatment (surgery and/or radiother-
apy) alone and 5-year survival in the late 1960s was
only 28%. Since then the addition of multiagent cyto-
toxic chemotherapy and the routine availability and
entry to clinical trials managed by the Children’s
Cancer and Leukaemia Group, formerly the United
Kingdom Children’s Cancer Study Group, have led to
serial improvement in 5-year survival for childhood
cancer. Seventy eight percent of those under 15 years
at diagnosis now survive at least 5 years.2 Acute
lymphatic leukaemia, the commonest malignancy in
childhood and universally fatal before the use of cyto-
toxic chemotherapy, was the ﬁrst to show improve-
ment followed by other haematological malignancies
and the solid malignancies of childhood.
The deﬁnition of ‘long-term survival’ varies
between those alive 5 years from diagnosis and 5
years after the end of treatment. As yet, there are rela-
tively few 50-year survivors but the number in each
decade of survival continues to increase. However,
the long-term survival cohort still has a shortened
life span compared with the normal population.
Between 5 and 10 years after diagnosis the major
cause of death is from the persistence or recurrence
of the original cancer. Increasingly, with lengthening
time after treatment, complications resulting from the
treatment itself take their toll and can aﬀect every
organ, tissue and system in the body.3
Second neoplasms diﬀerent from the original trea-
ted cancer are the most common cause of death after
recurrence and accrue steadily over time from end of
treatment with a rapid increase after 30 years of follow
up.3 Breast cancer after mantle radiotherapy for
Hodgkin’s disease is well known and there are guide-
lines for screening.4 Sarcomas are more common than
carcinomas and most are associated with radiother-
apy.5 Consent for radiotherapy in children should
involve detailed information about possible complica-
tions including the risk of second tumours.
The commonest site for second neoplasms in chil-
dren treated in the UK is the central nervous system
(CNS).5 These follow treatment for primary CNS
tumours, which as a group are the commonest solid
malignancy of childhood, prophylactic brain irradi-
ation for acute lymphatic leukaemia which was rou-
tine in the 1970s and early 1980s and after head and
neck radiation impinging on the base of the brain.
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In a recent study, over half (55%) of second neo-
plasms following brain irradiation in children in the
UK were meningiomas and 30% gliomas, occurring
between 5 and 52 years after treatment (mean 20.5
years).6 After irradiation of a primary brain tumour
there was a cumulative incidence for meningiomas of
6.3% by 40 years, representing a risk relative to the
general population of approximately 500-fold.
Methods
As a result of this clear information a medical multi-
specialty working group met, sponsored by the Royal
College of Radiologists. We shared knowledge on
epidemiology, diagnosis and management of men-
ingiomas and debated whether or not routine screen-
ing of those at increased risk should be advised.
Current knowledge on the subject was pooled and
together with our recommendations was used to
create the document: ‘Meningioma as a late eﬀect
of cancer treatment’ published online by the Royal
College of Radiologists in April 2013.7
What follows is a short summary of that document.
Epidemiology
Meningiomas, tumours of the meninges, the thin-
layered membrane surrounding the brain, occur
sporadically in the absence of known aetiology and
overall are the commonest brain tumour. Their appar-
ent incidence is increasing as more are registered and
more are found incidentally with scanning and an
ageing population. The most recent statistics from
the United States Central Brain Tumour Registry8
conﬁrm their rarity in childhood (0.1/100,000) and a
strikingly increased incidence with age reaching
49/100,000 in over 85 year olds. Women have an
approximately double incidence and there is an asso-
ciation with neuroﬁbromatosis type 2.9 Since 2004 it
has been mandatory to register unbiopsied tumours
diagnosed on scanning; 98% of meningiomas in the
most recent report were given a non-malignant code.8
An increased incidence with radiation exposure
has been recognized since the 1970s and has been
seen in atomic bomb survivors,10 after scalp irradi-
ation for tinea capitis,11 after full mouth dental X-
rays (when doses were higher than now)12 and after
cranial or spinal irradiation.6,13 Higher radiation
doses and longer interval after irradiation increase
the risk of meningioma development.6
Diagnosis
Symptoms are of new neurological deﬁcit, seizures,
raised intracranial pressure, proptosis, cavernous
sinus syndrome or a lump on the skull. These
prompt a scan (CT or MRI) which shows a well-cir-
cumscribed dural-based contrast enhancing mass;
multiple lesions can occur. The radiological appear-
ance is usually characteristic although histopathology
is necessary to distinguish between benign WHO
grade I with low recurrence risk, atypical grade II
with increased cellularity and mitoses, and anaplastic
grade III with frank features of malignancy and the
ability to invade other structures.14
Specific features of radiation-associated
meningiomas
While both sporadic- and radiation-induced meningi-
omas are usually benign, those associated with radi-
ation show behaviour which reﬂects the ﬁnding that
20–40% of radiation-associated meningiomas com-
pared with <10% sporadic meningiomas demon-
strate atypical or malignant features.11,15,16 They are
more likely to be invasive and to recur than sporadic
ones and in addition are more likely to be multiple
(5–15% vs. <5%).15 Both sporadic- and radiation-
associated meningiomas can recur even after appar-
ent total resection.
Cytogenetic diﬀerences are also seen. Deletions of
chromosome 1 have been reported in over 75% of
radiation-associated meningiomas compared with
the more usual deletions of chromosome 22 seen in
sporadic forms.15 Most series of radiation-associated
tumours show a lower female preponderance than
control groups11,15 and a younger mean age at pres-
entation (30–40 years after radiation for solid
tumours,16 65 years for sporadic tumours8).
Management
The options include watch and wait with serial scan-
ning for asymptomatic cases picked up incidentally,17
surgery for accessible and radiotherapy for inaccess-
ible sites. Complete and safe resection is often not
possible because of the tendency for radiation-
induced meningiomas to be multiple, invasive and
atypical or malignant.11,16 In addition, surgical heal-
ing can be compromised when prior radiotherapy has
left a relatively avascular scalp.16 When re-irradiation
is necessary newer techniques such as stereotactic
radiotherapy18 and intensity-modulated radiation
treatment19 and alternative radiation modalities
(e.g. Protons)20 might beneﬁt.
Long-term follow-up after childhood cancer
While two-thirds of survivors of childhood cancer
have one or more late eﬀects and one-third are
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signiﬁcantly aﬀected,21 historically only about half
were followed up beyond 5 years after the end of
treatment.22
Ongoing care of those who have been treated for
cancer in childhood is recommended. The British
Childhood Cancer Survivors Study has questionnaire
information on 10,000 long-term survivors, with
details on physical and psychological wellbeing.23
This, together with a similar, though USA hospital
based, Childhood Cancer Survivors Study has pro-
vided solid information on the incidence and severity
of late eﬀects.3,24
In 2008, NHS Improvement launched a Survivors’
Initiative to address long-term follow-up in survivors
of childhood and adult cancers.25 The Scottish
Intercollegiate Guidelines Network has recently
updated its recommendations on long-term follow-
up and this SIGN guidance number 132 has been
adopted by the National Institute for Clinical
Excellence for the whole of the UK.26
Personal treatment summaries containing known
risks of late eﬀects and access to multidisciplinary
long-term follow-up clinics for childhood cancer sur-
vivors are now expected. All survivors of childhood
cancer will be provided with a contact number and
will be contacted. Those at substantial risk will be
invited to be seen by a nurse or doctor every year
or less frequently as appropriate. (Children who are
still growing need to be seen three or four times a year
by an endocrinologist to ensure optimal ﬁnal height.)
Should routine scanning be suggested?
The group debated long and hard about formal
screening with MRI scans for those at risk of men-
ingioma development.
We agreed the importance of survivors being made
aware of their risks and that symptoms should be
reported. However, we concluded that the physical
risks of a new neurological disability or healing prob-
lems associated with surgery, in addition to the psy-
chological risks from knowledge of an asymptomatic
but not easily resectable lesion, from repeated waits
‘in limbo’ for scan results and from ﬁnding indeter-
minate white matter changes which often follow radi-
ation, outweighed any advantage in the early
detection of an asymptomatic lesion.
In addition, although gliomas would also be
detected by scanning there has been no demonstrable
beneﬁt from intervention when asymptomatic.
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